



**Fremtidens kræftpatienter vil blive behandlet individuelt
(Future cancer patients will be treated individually)**

**InvestorUgen, Dansk Aktionær
Forening, 12. Nov. 2020**

Agenda Topics

- Key messages
- 2cureX in brief
- The IndiTreat[®] test
- Clinical validation and pipeline
- Commercial roadmap
- Why invest in 2cureX



Ole Thastrup
CEO



Maarten van der Linden
CBO

Key-messages

- **2cureX is meeting a tremendous medical need**
- **2cureX has introduced the world's first CE-marked and ISO13485 compliant Microtumor test (IndiTreat)**
- **IndiTreat® commercially launched at ESMO (October 2020)**
- **2cureX has a strong clinical pipeline in major cancers**
- **2cureX has a strong financial position**

- because cancer patients are individuals



2cureX

2cureX in brief

2007

2cureX spun-out from Carlsberg Research Center (2007)



2015

2cureX GmbH established in Hamburg



2017

Clinical trial in Colorectal Cancer initiated

2018-2019

Management team expanded with CBO, CFO and CMO



2018-2020

2nd family of patents issued



2020

Last patient enrolled in Colorectal Cancer trial

2020 - Commercialization



2009

1st family of patents issued



2017

2cureX listed on Nasdaq First Nord Growth Market (Stockholm)



2018

Clinical trials in Ovarian and Pancreatic Cancer initiated

2019

Capital raise through a Rights Issue



2020

Capital raise through a Directed Issue



2020


Commercial launch of IndiTreat-CRC at ESMO



- because cancer patients are individuals

2cureX

Problem: Drug therapy in cancer often fails...




On average the percentage of the population for whom a particular drug in a specific disease area was ineffective

"... because cancer patients are individuals"


- because cancer patients are individuals

IndiTreat® - in real life

Ineffective medical treatment




Effective medical treatment selected by IndiTreat®




- because cancer patients are individuals

Strong Product pipeline




- because cancer patients are individuals

IndiTreat[®] in colorectal cancer (1)




Patient-derived microtumors

- Mimic the biological features of the primary tumor
- Maintain cell-cell and cell-matrix interactions
- Replicate the tumor microenvironment



Stage IV patients

Patient



- because cancer patients are individuals

IndiTreat® in colorectal cancer (2)



Last patient enrolled (Oct 2020)



Patient data will be assembled and analysed end of 2020

The trial will answer three essential questions:



- Can a microtumor functional test be conducted on needle biopsies from liver metastasis ?
- Can IndiTreat predict drug resistance ?
- Can IndiTreat improve patient outcome ?



Publication of results in Q1 2021

Principal Investigator: Lars Henrik Jensen; Chief Oncologist University Hospital Vejle



Interim analysis in Febr. 2019:

“The present data showed that it is feasible to tailor-make treatment using a functional test like IndiTreat®”



Funded by the Horizon 2020 Framework Programme of the European Union



- because cancer patients are individuals



European IndiTreat® Market

2cureX operates in a highly attractive market



Total available market for IndiTreat® testing in Europe

Colorectal cancer
Ovarian cancer
Pancreatic cancer

} 700.000 new
cases per year
in Europe

- because cancer patients are individuals



Commercial Roadmap 2021 - 2023

	2021	2022	2023
Product Focus	Colorectal	Colorectal, Ovarian , Pancreatic	4 – 5 Indications
Market Focus	Nordics	EU markets + UK	EU markets + UK + Selected Asian markets
Target Customers	Key cancer centers	Larger Regional Hospitals	General Hospitals
Sales Organization	Own sales reps (n=5) IVD distributors	Own sales organization (n=10) IVD distributors	Own sales organization (n=20) Global IVD partner ?
Sales Process	Evaluation deals Early-stage pricing	Commercial Deals	Commercial Deals
Product development	Pancreatic, Ovarian Automation	Breast, Immuno Oncology Automation	

- because cancer patients are individuals

A strong Clinical and Commercial partner base is in place

Group 1 Clinical trials Partners



Group 3 Patient societies



Group 5 Patient stratification partners



Group 2 Academic + Technical Partners




Group 4 Commercial Partners / Sales Channels



- because cancer patients are individuals

“I am convinced that IndiTreat® is the missing piece of the cancer treatment puzzle”



Henrik Harling
Chief Medical Officer, 2cureX



- because cancer patients are individuals

Why invest in 2cureX ?

- There is a tremendous medical need for making cancer treatment more effective – 2cureX has the “puzzle piece” for making this possible
- 2cureX has introduced the world’s first CE-marked and ISO13485 compliant Microtumor test (IndiTreat®)
- IndiTreat® is patent protected in major markets
- 2cureX has a strong clinical pipeline in four major cancers
- 2cureX has a strong financial position allowing execution of commercialization plan

Follow us by signing up
for News on
www.2curex.com
and on:



Thank for your attention !